Skip to content

Don't be Late! Postponing Cognitive Decline and Preventing Early Unemployment in People With Multiple Sclerosis

Don't be Late! Postponing Cognitive Decline and Preventing Early Unemployment in People With Multiple Sclerosis

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06068582
Acronym
DBL
Enrollment
270
Registered
2023-10-05
Start date
2023-04-16
Completion date
2026-09-30
Last updated
2025-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis

Keywords

Multiple Sclerosis, Cognition, Exercise, Employment, Prevention, Health-related Quality of Life

Brief summary

The goal of this randomized controlled trial is to compare the effectiveness of two innovative interventions aimed at preventing cognitive decline and work-related problems to enhanced usual care in improving quality of life in people with multiple sclerosis. Secondary objectives are: * to compare the effectiveness of the investigated interventions in improving cognitive, psychological, and work functioning, and in enhancing the brain's functional network * to examine which factors (i.e., baseline cognitive, psychological, work, and brain MRI-parameters) are predictive of the response to the investigated interventions * aim to qualitatively reflect on the process and outcome of the investigated interventions considering the perspectives of relevant stakeholders to allow for smooth and successful implementation in clinical practice Participants will follow the intervention for four months, with follow-up measurements at six months after intervention and 12 months after intervention.

Detailed description

Background Up to 65% of the people with multiple sclerosis (PwMS) develop cognitive deficits that severely affect daily life functioning and PwMS' quality of life. Moreover, approximately 65% of all patients end up unemployed within five years after diagnosis. Current treatments mostly focus on symptom management and return to work, which may be too late. It is hypothesized that timely interventions will help prevent or delay cognitive decline and work-related problems in PwMS, thereby improving quality of life. Objectives Primary Objective: To compare the effectiveness of the investigated interventions with enhanced usual care in improving quality of life. Secondary Objectives: 1. To compare the effectiveness of the investigated interventions in improving cognitive, psychological and work functioning, and in enhancing the brain's functional network. 2. To examine which factors (i.e. baseline cognitive, psychological, work and brain MRI-parameters) are predictive of the response to the investigated interventions. 3. To qualitatively reflect on the process and outcome of the investigated interventions considering the perspectives of relevant stakeholders to allow for smooth and successful implementation in clinical practice. 4. To compare the cost-effectiveness of the investigated interventions. Material and methods A randomized controlled trial with three arms and three follow-up visits over a total time period of 16 months. During these visits researchers will gather information from questionnaires, neuropsychological examination, MRI and blood sampling. All participants (N= 240) have a confirmed MS diagnosis according to the McDonald 2017 criteria, have subclinical cognitive impairment and are aged between 18 and 67. Participants will be randomly assigned to one of the three arms (N=90 in each arm). Interviews will be conducted with 12-15 participants from both interventions, 10-12 sport coaches, 8-12 work coaches and 10-12 supervisors from the workplace. 'Strengthening the brain' (4 month-program) consists of weekly 30 minutes 1-on-1 exercise and lifestyle coaching in combination with two moments per week unsupervised exercises at home and a home-based online computerized cognitive training. 'Strengthening the mind' (4 month-program) consists of biweekly contact with work coaches who are all diagnosed with MS themselves. 'Enhanced usual care' entails an appointment with a researcher in addition to usual care. Results The primary outcome is change in quality of life as measured with the 36-item Short Form. Several secondary outcomes will be collected: cognitive, psychological, cost-effectiveness, structural- and functional brain, neurological, physiological, and qualitative measures.

Interventions

BEHAVIORALStrenghtening the brain

Lifestyle intervention containing physical exercise, lifestyle coaching, and cognitive training. The programme contains weekly 30 minutes 1-on-1 fitness and lifestyle coaching with two moments of exercise at home for 20 minutes. Online computerized cognitive training will be done for 60 minutes per week.

BEHAVIORALStrengthening the mind

Work-focused intervention combining the capability approach and the participatory approach. Together with a work-coach who has been diagnosed with MS themselves, participants will assess important work values, discover challenges participants are facing, think of solutions for these challenges, develop a plan of action and implement these solutions.

Sponsors

Universiteit Leiden
CollaboratorOTHER
Personal Fitness Nederland
CollaboratorUNKNOWN
MS Vereniging Nederland
CollaboratorUNKNOWN
Merck BV
CollaboratorUNKNOWN
Genzyme, a Sanofi Company
CollaboratorINDUSTRY
MS Sherpa
CollaboratorUNKNOWN
Amsterdam UMC, location VUmc
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Investigator, Outcomes Assessor)

Masking description

Randomization will be done by investigators who are not involved in data collection and analyses. Intervention will be carried out by people not involved in data collection and analyses

Eligibility

Sex/Gender
ALL
Age
18 Years to 67 Years
Healthy volunteers
No

Inclusion criteria

* Confirmed MS diagnosis according to the McDonald 2017 criteria * Age between 18 and 67 * No changes in disease modifying therapy prior to inclusion (i.e., no changes in last 3 months) - this criterion only applies at inclusion to ensure participants are in a stable situation at the start of the study and for follow-up measures, changes in treatment will be registered but will not result in exclusion from the study * no current relapse or steroid treatment in the six weeks prior to study visits * presence of mild cognitive deficits (at least one test with a Z-score of -1.0 to -1.99 below norm scores of healthy controls on the Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS) battery * being able to participate in an exercise intervention (i.e., EDSS \< 6.0) * fulfilling safety criteria for MRI (no metal inside body, not pregnant, no claustrophobia)

Exclusion criteria

* presence of neurological (other than MS) and psychiatric disorders * a current or history of drug or alcohol abuse * being unable to speak or read Dutch * currently on sick leave for a period of 6 weeks or longer * currently pregnant

Design outcomes

Primary

MeasureTime frameDescription
Quality of LifeBaseline, Month 4, Month 10, and Month 16Quality of life assessed using the 36-item Short Form. Item-scores are summed and transformed into a total score that ranges 0-100. Higher score corresponds with better quality of life.

Secondary

MeasureTime frameDescription
Verbal fluencyBaseline, Month 4, Month 10, and Month 16Verbal fluency is assessed using the Dutch adaptation of the Controlled Oral Word Association Test; Dutch Letter Fluency Test. Total number of correct words will be administered. Higher score corresponds with better verbal fluency.
Spatial ProcessingBaseline, Month 4, Month 10, and Month 16Spatial Processing is assessed using the Judgement of Line Orientation. Total correct responses, with maximum 30, will be administered. Higher score corresponds with better spatial processing.
Verbal New Learning and MemoryBaseline, Month 4, Month 10, and Month 16New Learning and Memory is assessed using the California Verbal Learning Test, second edition (CVLT-II). Direct recall on the CVLT-II will be administered using number of correctly remembered items over learning trials 1-5. Delayed recall on CVLT-II will be administered using number of correctly remembered items 20 minutes after learning trail 5. Maximum scores for direct recall, delayed recall, and recognition are set at 80, 16, and 44, respectively. Higher score equals better verbal learning and memory.
Visual New Learning and MemoryBaseline, Month 4, Month 10, and Month 16New Learning and Memory is assessed using the Brief Visuospatial Memory Test-Revised (BVMT-R). Direct recall on BVMT-R will be administered using number of correctly remembered items over learning trials 1-3. Delayed recall on BVMT-R will be administered using number of correctly remembered items 25 minutes after learning trail 3. Maximum scores for direct recall, delayed recall, and recognition are set at 36, 12, and 12, respectively. Higher score equals better visual learning and memory.
Executive FunctionBaseline, Month 4, Month 10, and Month 16Executive Function is assessed using the Delis-Kaplan Executive Function System. Total correct sorts will be administered, with a maximum of 16 sorts. A higher score suggests better executive functioning.
Self-Reported Cognitive FunctioningBaseline, Month 4, Month 10, and Month 16Self-Reported Cognitive Functioning is assessed using the Multiple Sclerosis Neuropsychological Screening Questionnaire. Maximum score of 70 can be reached, with a score of 27 or higher indicating presence of neuropsychological problems.
Work Participation and ProductivityBaseline, Month 4, Month 10, and Month 16Work Participation and Productivity is assessed using the Work Productivity and Activity Impairment Questionnaire: General Health, which administers the effect of health-problems on ability to work. Scores are calculated as percentages, with higher numbers indicating greater impairment and less productivity.
Work DifficultiesBaseline, Month 4, Month 10, and Month 16Work Difficulties are assessed using the Multiple Sclerosis Work Difficulties Questionnaire. The questionnaire consists of 23 items, which can be grouped into three subscales: psychological/cognitive barriers, physical barriers, and external barriers. The maximum score of each subscale is 100, with higher scores indicating higher perceived difficulties. Total score consists of an average of the three subscale scores.
Capability to carry out Work ActivitiesBaseline, Month 4, Month 10, and Month 16Capability to carry out Work Activities is assessed using the Capability Set for Work Questionnaire. This questionnaire evaluates for seven valued work aspects whether, A) it is important to the worker, B) their work offers sufficient opportunities to do it, and C) it can be achieved, on a 5-point Likert scale.
Quality of Working LifeBaseline, Month 4, Month 10, and Month 16Quality of Working Life is assessed using the Quality of Working Life Questionnaire for Cancer Survivors. The questionnaire consists of five subscales: meaning of work, perception of the work situation, atmosphere in the work environment, understandings and recognition in the organisation, and problems due to health situation. The overall score and sum scores of the subscales are calculated with a standardised score 0-100. Higher score corresponds with better quality of working life.
Grey Matter Volume of the BrainBaseline, Month 4, and Month 16Grey Matter Volume will be determined using FSL-SIENAX, after lesion filling on the 3DTI.
White Matter Volume of the BrainBaseline, Month 4, and Month 16White Matter Volume will be determined using FSL-SIENAX, after lesion filling on the 3DTI.
Total Brain VolumeBaseline, Month 4, and Month 16Total Brain Volume will be determined using FSL-SIENAX, after lesion filling on the 3DTI.
Volumes of Deep Grey Matter StructuresBaseline, Month 4, and Month 16Volumes of Deep Grey Matter Structures will be determined using FIRST.
Cortical ThicknessBaseline, Month 4, and Month 16Cortical Thickness will be determined using Freesurfer.
White Matter IntegrityBaseline, Month 4, and Month 16White Matter Integrity will be determined using Diffusion Tensor Imaging
Information processing speedBaseline, Month 4, Month 10, and Month 16Information processing speed is assessed using the Symbol Digit Modalities Test (SMDT). The total responses made in 90 seconds is administered. Higher amount of correct responses equals better information processing speed.
Regional Functional ActivationBaseline, Month 4, and Month 16Regional Functional Activation will be determined using Task-Based fMRI
Societal Costs including Healthcare, Patient, and familyBaseline, Month 4, Month 10, and Month 16Societal Costs will be assessed using the iMTA Medical Consumption Questionnaire.
FatigueBaseline, Month 4, Month 10, and Month 16Fatigue will be assessed using the Checklist Individual Strength. The questionnaire consists of 20 items, scored on a 7-point Likert scale. Fatigue is a subscale of the questionnaire, and is scored by adding the scores of the items, where a higher score corresponds with more fatigue.
Mood and AnxietyBaseline, Month 4, Month 10, and Month 16Mood and Anxiety will be assessed using the Hospital Anxiety and Depression Scale. The questionnaire consists of 14 items on a 4-point Likert scale. The range of scores is 0-21 where a higher score equals more complaints of anxiety and depression.
ResilienceBaseline, Month 4, Month 10, and Month 16Resilience will be assessed using the Connor Davidson Resilience Scale. Total score ranges 0-100, with higher scores reflecting greater resilience.
Perceived Level of StressBaseline, Month 4, Month 10, and Month 16Perceived Level of Stress will be assessed using the Perceived Stress Scale. Total score ranges 0-40, with higher scores indicating higher perceived stress.
Social MindfulnessBaseline, Month 4, Month 10, and Month 16Social Mindfulness will be assessed using the SoMi paradigm by van Doesum et al. (2013). Choices that are made are scores as mindful (1) or unmindful (0). Final score will be computed by averaging the scores over all decisions, resulting in a number between 0 (unmindful) and 1 (mindful).
Social ParticipationBaseline, Month 4, Month 10, and Month 16Social Participation will be assessed using the PROMIS 'Ability to Participate in Social Roles and Activities' item bank. The questionnaire consists of eight items that can be scored on a 5-point Likert scale. Higher scores indicate better ability to participate in social roles and activities.
MS-related disabilityBaseline, Month 4, Month 10, and Month 16MS-related disability will be assessed using the Expanded Disability Status Scale. This scale ranges from 0.0 to 10.0, where a higher score indicates worse disability.
BalanceBaseline, Month 4, and Month 16Balance will be assessed using the Mini-BESTest. The test contains 14 items where a total score of 28 points can be achieved, where a score \<19 induces an increased risk of falling.
Walking SpeedBaseline, Month 4, and Month 16Walking Speed will be assessed using the Timed 25-Foot Walk.
EnduranceBaseline, Month 4, and Month 16Endurance will be assessed using the Shuttle Walk Test according to the protocol of Singh et al. (1992).
Grip StrengthBaseline, Month 4, and Month 16Grip Strength will be assessed using a JAMAR hand-held dynamometer.
Upper Limb DexterityBaseline, Month 4, and Month 16Upper Limb Dexterity will be assessed using the 9-Hole Peg Test and the Purdue Pegboard Test.
Lost Productivity CostsBaseline, Month 4, Month 10, and Month 16Lost Productivity Costs will be assessed using the iMTA Productivity Cost Questionnaire. The questionnaire consists of three modules measuring absenteeism, presenteeism, and productivity loss from unpaid work.
Quality Adjusted Life YearsBaseline, Month 4, Month 10, and Month 16Quality Adjusted Life Years will be assessed using the EuroQol five-dimensional Questionnaire. The questionnaire comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Higher scores indicate more problems considering the dimensions.
Functional ConnectivityBaseline, Month 4, and Month 16Functional Connectivity will be determined using Resting-State fMRI

Countries

Netherlands

Contacts

Primary ContactJip Aarts
j.aarts@fsw.leidenuniv.nl+31 71 5275081
Backup ContactShalina Saddal
s.saddal@amsterdamumc.nl+31 20 566 38 01

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026